Results 1 to 10 of about 820,649 (291)
Editorial: Sigma Receptors [PDF]
Frontiers in Pharmacology, 2020 Sigma receptors were initially described as opioid receptors (Martin et al., 1976). They are now considered neither related to other types of receptor nor to each other. While several ligands used to study these receptors [e.g., di-O-tolyl guanidine (DTG) and haloperidol] have similar affinities for the sigma-1 and sigma-2 receptors, these proteins ...
Ebru Aydar +4 more
doaj +7 more sources
Sigma receptors and neurological disorders. [PDF]
Pharmacol Rep, 2021 AbstarctSigma receptors were identified relatively recently, and their presence has been confirmed in the central nervous system and peripheral organs. Changes in sigma receptor function or expression may be involved in neurological diseases, and thus sigma receptors represent a potential target for treating central nervous system disorders.
Piechal A, Jakimiuk A, Mirowska-Guzel D.
europepmc +6 more sources
The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD) [PDF]
Frontiers in Pharmacology, 2019 Sigma receptors, including Sigma-1 receptors and Sigma-2 receptors, are highly expressed in the CNS. They are intracellular chaperone proteins. Sigma-1 receptors localize mainly at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM ...
Kai Yang +3 more
doaj +4 more sources
The Sigma Enigma: A Narrative Review of Sigma Receptors. [PDF]
Cureus, 2023 The sigma-1 and sigma-2 receptors were first discovered in the 1960s and were thought to be a form of opioid receptors initially. Over time, more was gradually learned about these receptors, which are actually protein chaperones, and many of their unique or unusual properties can contribute to a range of important new therapeutic applications.
Pergolizzi J +6 more
europepmc +3 more sources
Contribution of Lysosome and Sigma Receptors to Neuroprotective Effects of Memantine Against Beta-Amyloid in the SH-SY5Y Cells [PDF]
Advanced Pharmaceutical Bulletin, 2020 Purpose: Memantine is an approved drug for the treatment of Alzheimer’s disease (AD). Autophagy, lysosome dysfunction, and sigma receptors have possible roles in the pathophysiology of AD.
Mojtaba Keshavarz +3 more
doaj +2 more sources
Role of Sigma Receptors in Alcohol Addiction [PDF]
Frontiers in Pharmacology, 2019 Pharmacological treatments for alcohol use disorder (AUD) are few in number and often ineffective, despite the significant research carried out so far to better comprehend the neurochemical underpinnings of the disease.
Sema G. Quadir +2 more
doaj +2 more sources
Sigma Receptors as Endoplasmic Reticulum Stress “Gatekeepers” and their Modulators as Emerging New Weapons in the Fight Against Cancer [PDF]
Frontiers in Pharmacology, 2018 Despite the interest aroused by sigma receptors (SRs) in the area of oncology, their role in tumor biology remains enigmatic. The predominant subcellular localization and main site of activity of SRs are the endoplasmic reticulum (ER). Current literature
Anna Tesei +10 more
doaj +2 more sources
Sigma Receptors and Alcohol Use Disorders. [PDF]
Handb Exp Pharmacol, 2017 Although extensive research has focused on understanding the neurobiological mechanisms underlying alcohol addiction, pharmacological treatments for alcohol use disorders are very limited and not always effective. This constraint has encouraged the search for novel pharmacological targets for alcoholism therapy.
Sabino V, Cottone P.
europepmc +3 more sources
Sigma Receptors and Substance Use Disorders. [PDF]
Adv Exp Med Biol, 2017 Thanks to advances in neuroscience, addiction is now recognized as a chronic brain disease with genetic, developmental, and cultural components. Drugs of abuse, including alcohol, are able to produce significant neuroplastic changes responsible for the profound disturbances shown by drug addicted individuals.
Sabino V, Hicks C, Cottone P.
europepmc +3 more sources
Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction [PDF]
NeurotherapeuticsMemory impairment is among the most disabling features of depression and schizophrenia, yet remains largely untreated by available pharmacotherapies.
Kinga Sałaciak +16 more
doaj +2 more sources